From Patient Data to Commercial Decision-Making
Real-world data in life sciences spans claims records, electronic health records, lab results, genomics, and payer data — all generated outside the controlled conditions of clinical trials. The analytical challenge is integrating these heterogeneous sources into coherent, decision-ready insights at scale. Teams working in commercial strategy, medical affairs, and clinical development increasingly rely on purpose-built platforms to navigate this complexity.
At the patient level, longitudinal data across care settings reveals how disease progresses, how treatment patterns shift, and where gaps in care exist — intelligence that informs both market positioning and trial design. In oncology specifically, the intersection of clinical, genomic, and outcomes data is reshaping how sponsors identify eligible patients, build synthetic cohorts, and generate post-approval evidence.
On the commercial side, understanding provider behavior, referral networks, and patient population characteristics is foundational to targeting strategy. Tools in this domain bring together disparate data assets — often with AI-driven analytics — to help teams move from raw data to actionable intelligence across the full product lifecycle.
Real-World Evidence Software by Specialisation
Tools that aggregate and analyze healthcare provider profiles, patient claims, and market data to enable provider identification, audience segmentation, territory optimization, and commercial go-to-market strategy in life sciences.
Tools that leverage real-world oncology data -- including EHR, claims, and genomics -- to support patient identification, cohort building, clinical trial recruitment, and evidence generation for drug development and commercial decision-making.
Tools that aggregate and analyze real-world patient-level data across claims, EHR, lab, and payer sources to generate commercial, clinical, and market insights across large patient populations.
Real-World Evidence Software: Common Challenges
- Fragmented patient data across care settings
Patient journeys span multiple providers, payers, and labs, making it difficult to reconstruct complete longitudinal records without integrated data platforms.
- Identifying trial-eligible patients at scale
Locating patients who meet specific clinical or genomic criteria across real-world datasets is time-consuming without dedicated cohort-building infrastructure.
- Opaque HCP prescribing and referral patterns
Commercial teams lack visibility into provider behavior and network dynamics, limiting the precision of targeting and territory planning efforts.
- Slow evidence generation post-approval
Building real-world evidence for regulatory or payer submissions requires structured access to outcomes data that few organizations can assemble internally.
- Misaligned market sizing and segmentation
Estimating addressable patient populations or provider segments without claims and EHR data routinely leads to inaccurate forecasts and misallocated resources.
- Poor signal from undifferentiated market data
Generic market research rarely captures the disease-level specificity needed for credible commercial or clinical strategy in competitive therapeutic areas.
Real-World Evidence Software Use Cases
- Commercial launch planning in new indications
Brand teams use patient-level claims and EHR data to define the addressable market and prioritize provider segments ahead of a product launch.
- Oncology cohort building for trial recruitment
Clinical operations teams use genomic and EHR data to identify and pre-qualify patients meeting trial eligibility criteria before site activation.
- Generating real-world evidence for payer submissions
HEOR and medical affairs teams assemble retrospective patient cohorts to demonstrate comparative effectiveness for formulary or reimbursement negotiations.
- Territory design and field force optimization
Commercial analytics teams use provider-level data to align sales territories with actual prescribing volume and patient population distribution.
- Tracking treatment patterns after approval
Medical affairs teams monitor how an approved therapy is being used in real-world practice compared to label indications and clinical trial populations.
- Competitive landscape analysis by disease area
Strategy teams use market intelligence platforms to assess prescribing trends, patient share, and competitive dynamics within a specific therapeutic area.
Evaluating Real-World Evidence Software: Key Questions
- What real-world data sources are included, and how frequently are they refreshed?
- How are patient records de-identified and linked across claims, EHR, and lab datasets?
- Does the platform support custom cohort definitions using clinical or genomic criteria?
- What is the geographic and care-setting coverage of the underlying patient population?
- How are AI-derived insights validated against clinical ground truth or published benchmarks?
Is Real-World Evidence Software Right for Your Team?
- Your team makes decisions based on patient population size, treatment patterns, or disease epidemiology drawn from real-world sources.
- You need to identify, segment, or prioritize healthcare providers based on prescribing behavior, patient volume, or network affiliation.
- Your organization is generating real-world evidence for regulatory, payer, or publication purposes using retrospective patient data.
- You are designing or recruiting for clinical trials and need to validate feasibility or locate eligible patients using EHR or claims data.
- Your commercial or medical affairs strategy depends on understanding how a therapy is used outside of controlled trial conditions.
Example Tools On Our Platform
Genialis Supermodel- RNA-based biomarker discovery and cancer biology interpretation for treatment response prediction and clinical decision-making.
Link- Patient-level linkage of clinical trial data with real-world data for continuous evidence generation and long-term follow-up.
Aetion Discover- Visual-first analytics for rapid, hypothesis-driven insights from real-world data without programming expertise.
BC Catalyst- AI-powered cohort building, biomarker discovery, and population health insights for precision medicine across the drug lifecycle.
Fit-for-Purpose Data Tool- Real-world data selection and assessment for clinical trial design and regulatory decision-making.
Basil MedTech Intel - Commercial Intelligence- Real-time regulatory and market monitoring for medical device competitors, approvals, clinical trials, and post-market events.
Related Life Science Software
- Genomics & Omics Analysis
Oncology RWD platforms increasingly incorporate genomic profiles to stratify patient cohorts and support biomarker-driven trial design.
- Clinical Trial Management
Real-world patient identification and cohort data feed directly into trial feasibility assessment and recruitment planning workflows.
- Commercial & Medical Affairs
Market intelligence and HCP targeting outputs are operationalized within commercial and medical affairs execution platforms.
- Clinical & Health Data Management
Standardized clinical data infrastructures are a prerequisite for integrating and querying multi-source real-world patient records.
- Research Intelligence & Discovery
Scientific literature and clinical evidence inform how RWD findings are interpreted and translated into research or commercial strategy.